2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

• Published in: Clinical and molecular hepatology Vol. 28; no. 4; pp. 583 - 705
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Association for the Study of the Liver 01.10.2022; The Korean Association for the Study of the Liver
• Subjects: Cancer therapies; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - therapy; Contrast agents; Disease prevention; Guideline; Hepatitis B; Hepatitis B, Chronic - complications; Hepatitis C; Humans; Liver cancer; Liver cirrhosis; Liver diseases; Liver Neoplasms - diagnosis; Liver Neoplasms - pathology; Liver Neoplasms - therapy; Male; Patients; Prevalence; Republic of Korea - epidemiology; Surveillance; Republic of Korea; United States > US; South Korea; Hepatocellular carcinoma; Diagnosis; Management; Guidelines
• ISSN: 2287-2728; 2287-285X; 2287-285X
• DOI: 10.3350/cmh.2022.0294

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.